CVRx Reports Q2 2026 Results, Shows Revenue Growth But Maintains Net Loss
CVRx (CVRX) reported Q2 2026 revenue of $15.7M, up 16% from $13.6M a year earlier. U.S. revenue rose 21% to $14.8M, while Europe fell 31% to $0.9M. Gross profit increased to $13.7M and gross margin to 87%. Net loss narrowed to $14.0M. FY2026 revenue guidance is $58.0M to $60.0M.
How this was made
The 30-second read
Why it matters
Q2 showed revenue growth (+16% YoY) and higher gross margin (87%), with net loss narrowing, alongside a new Humana Medicare Advantage coverage policy effective May 1, 2026. Management also issued FY 2026 and Q3 2026 revenue guidance.
Market read
Traders can reassess CVRx’s near-term revenue trajectory using the new quarterly print, updated gross margin, and the FY/Q3 guidance, plus the incremental reimbursement catalyst from Humana.
What to watch
Active implanting centers and US units rose, but the article does not quantify how Humana coverage will impact future prescriptions or timing of reimbursement-driven revenue.
Background
CVRx is a commercial-stage neuromodulation medical device company focused on Barostim therapy for cardiovascular disease.
Ticker impact
CVRx reported Q2 2026 revenue of $15.7M (+16% YoY) and guided FY 2026 revenue to $58.0M-$60.0M while net loss narrowed.
Near-term bias depends on whether the market focuses on revenue/gross margin improvement versus ongoing net loss and the sharp overnight price move mentioned.
The article provides concrete quarterly financials, full-year and Q3 revenue guidance, and a new Humana Medicare Advantage coverage policy for Barostim therapy, all of which can drive repricing.
Market effects
Reimbursement progress for cardiovascular neuromodulation therapies can support sentiment across small-cap medtech names tied to coverage expansion.
Limited, since the article highlights a Europe revenue decline but no new Europe-specific catalyst.
Low, as the news is primarily US reimbursement and company-specific guidance.
Counterpoint
The revenue growth may not translate into profitability, and the Europe decline could offset US gains over time.
Key entities
- companyCVRx, Inc.
Reported Q2 2026 results, issued FY 2026 and Q3 2026 revenue guidance, and discussed Barostim reimbursement developments.
- payerHumana
Issued a Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026.
